Salmonella Enterica Enterica Serovar Typhi

The dosage for Salmonella Enterica Enterica Serovar Typhi depends entirely on the formulation prescribed by your healthcare provider. For the live attenuated oral vaccine (Ty21a), the standard adult regimen consists of four capsules. One capsule is taken every other day (e.g., days 1, 3, 5, and 7). All four doses must be completed at least one week before travel to ensure the immune system has sufficient time to respond. For the Vi capsular polysaccharide injectable vaccine, a single 0.5 mL (25 mcg) dose is administered intramuscularly. This should be given at least two weeks before potential exposure. Re-vaccination (boosters) is generally recommended every 2 years for the injectable form and every 5 years for the oral form if continued protection is required.

Pediatric dosing for Salmonella Enterica Enterica Serovar Typhi is strictly governed by age limits due to the maturity of the immune system and the ability to swallow capsules. The oral live attenuated vaccine is approved for children aged 6 years and older; the dosage is identical to the adult regimen (four capsules taken every other day). The injectable Vi polysaccharide vaccine is approved for children as young as 2 years of age, administered as a single 0.5 mL dose. It is not currently approved for children under the age of 2, as they often do not mount an effective immune response to polysaccharide antigens.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the vaccine components are not cleared through the kidneys in a manner that would cause systemic toxicity. However, the overall health of the patient should be assessed.

Hepatic Impairment

There are no established guidelines for dosage adjustment in hepatic impairment. The liver does not play a primary role in the processing of these vaccine antigens.

Elderly Patients

Clinical studies have not identified significant differences in safety or efficacy between elderly patients and younger adults. However, the immune response may be slightly diminished in those over 65, and healthcare providers should evaluate the necessity of vaccination based on specific travel risks.

For the oral capsules, specific administration is vital for efficacy. Capsules must be kept refrigerated (2°C to 8°C) until used. Each capsule should be swallowed whole approximately one hour before a meal with a cool or lukewarm drink (not exceeding body temperature). Do not crush or chew the capsules, as the enteric coating is necessary to protect the live bacteria from stomach acid. For the injectable form, a healthcare professional will administer the dose into the deltoid muscle of the upper arm. It is important to remain in the clinic for 15-30 minutes after injection to monitor for any immediate allergic reactions.

If a dose of the oral vaccine is missed, it should be taken as soon as remembered, and the every-other-day schedule should be adjusted accordingly. However, the entire four-dose series must be completed at least one week before travel. If the delay is significant, consult your healthcare provider, as the series may need to be restarted to ensure adequate immunity.

An overdose of the oral vaccine (e.g., taking more than one capsule at a time) is unlikely to cause serious harm but may increase the risk of gastrointestinal side effects like nausea or abdominal cramping. In the event of an accidental overdose, contact a poison control center or seek medical attention. For the injectable form, an overdose is rare as it is administered by a professional, but it could lead to increased local site reactions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip doses without medical guidance, as this may leave you unprotected against typhoid fever.

Side effects of Salmonella Enterica Enterica Serovar Typhi are generally mild and transient. For the oral vaccine, the most common side effects involve the gastrointestinal tract, including abdominal pain, nausea, and vomiting. These typically occur within 24 hours of taking a dose and last for approximately 1-2 days. For the injectable vaccine, local reactions at the site of injection are very common. Over 70% of patients report pain or tenderness at the injection site. Redness (erythema) and swelling (induration) are also frequently observed. These local effects are a sign that the immune system is responding to the antigen and usually resolve without treatment within 48 to 72 hours.

Systemic reactions can occur with both the oral and injectable forms. These include:

• Fever: A low-grade fever is common as the body mounts an immune response.
• Headache: Often described as a dull, tension-like ache that responds well to over-the-counter pain relievers.
• Malaise: A general feeling of discomfort or tiredness.
• Myalgia: Muscle aches, particularly in the limb where the injection was given.
• Diarrhea: Specifically associated with the oral live attenuated capsules.

Rarely, patients may experience more pronounced systemic symptoms. These can include significant chills, sweating, and arthralgia (joint pain). There have been isolated reports of skin rashes or urticaria (hives) following administration. While these are usually self-limiting, they should be reported to a healthcare provider to rule out a developing allergy.

> Warning: Stop taking Salmonella Enterica Enterica Serovar Typhi and call your doctor immediately if you experience any of these.

• Anaphylaxis: Although extremely rare, a severe allergic reaction can occur. Symptoms include difficulty breathing, swelling of the face or throat, rapid heartbeat, and a severe rash.
• High Fever: A fever exceeding 103°F (39.4°C) should be evaluated by a medical professional.
• Severe Abdominal Pain: While mild cramping is common with the oral form, intense or persistent pain may indicate a different underlying issue.
• Neurological Symptoms: Any signs of confusion, extreme dizziness, or fainting should be treated as an emergency.

There are no known long-term adverse effects associated with the Salmonella Enterica Enterica Serovar Typhi vaccine. Because it is a vaccine and not a chronic medication, the components are cleared from the body relatively quickly. The only "long-term" effect is the desired immunological memory that protects against typhoid fever. There is no evidence that this vaccine causes chronic autoimmune conditions or long-term gastrointestinal disorders.

No FDA black box warnings currently exist for Salmonella Enterica Enterica Serovar Typhi vaccines. These products are generally considered safe for the indicated populations when administered according to guidelines. However, the lack of a black box warning does not mean the drug is without risk; patients should always review the full prescribing information and discuss their medical history with a doctor.

Report any unusual symptoms to your healthcare provider. You may also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Salmonella Enterica Enterica Serovar Typhi vaccines are intended for the prevention of typhoid fever caused by S. Typhi and do not protect against other forms of Salmonella (such as those causing common food poisoning) or Paratyphoid fever. It is critical to understand that no vaccine is 100% effective; travelers should continue to practice safe food and water precautions (e.g., "boil it, cook it, peel it, or forget it") even after being vaccinated. The oral vaccine should not be started if the patient has an acute gastrointestinal illness, such as persistent diarrhea or vomiting, until the condition has resolved.

There are no FDA black box warnings for Salmonella Enterica Enterica Serovar Typhi. It is one of the more widely used travel vaccines with a well-established safety profile spanning several decades of global use.

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of severe allergic reactions to any component of the vaccine (including gelatin in the oral capsules) should not receive it. Epinephrine and other emergency measures must be available during administration of the injectable form.
• Immunocompromised Patients: The live attenuated oral vaccine (Ty21a) should not be administered to individuals with weakened immune systems due to HIV/AIDS, cancer, or immunosuppressive therapies (like high-dose steroids or chemotherapy). In these individuals, the attenuated bacteria could potentially cause an infection. The inactivated injectable vaccine is generally preferred for this population, though the immune response may be suboptimal.
• Acute Illness: Vaccination should be postponed in individuals suffering from an acute febrile illness (fever) or acute intestinal infection.
• Antibiotic Use: For the oral vaccine, recent or current use of antibiotics can kill the live attenuated bacteria in the vaccine, rendering it ineffective. A gap of at least 3 days between the last dose of antibiotics and the first dose of the vaccine is usually required.

Routine laboratory monitoring (such as blood counts or liver function tests) is not required for the administration of Salmonella Enterica Enterica Serovar Typhi. However, healthcare providers may monitor the patient's temperature and injection site for 30 minutes post-administration. In research settings, antibody titers (anti-Vi IgG) may be measured to confirm seroconversion, but this is not standard clinical practice for individual patients.

There is no evidence that Salmonella Enterica Enterica Serovar Typhi impairs the ability to drive or operate heavy machinery. However, if a patient experiences significant malaise or a high fever following vaccination, they should avoid these activities until they feel fully recovered.

While there is no direct contraindication between alcohol and the S. Typhi vaccine, it is advisable to avoid excessive alcohol consumption for 24-48 hours after vaccination. Alcohol can dehydrate the body and potentially worsen side effects like headache or malaise, making it difficult to distinguish between vaccine reactions and alcohol-related symptoms.

As this is a short-course vaccine (oral) or a single-dose vaccine (injectable), there is no "discontinuation" or tapering process. However, if the four-dose oral series is interrupted, the patient may not develop full immunity and should consult their doctor about restarting the series.

> Important: Discuss all your medical conditions, especially any immune system issues or recent illnesses, with your healthcare provider before starting Salmonella Enterica Enterica Serovar Typhi.

For the oral live attenuated Salmonella Enterica Enterica Serovar Typhi vaccine (Ty21a), the most critical contraindication is the concurrent use of systemic antibiotics. Antibiotics such as amoxicillin, ciprofloxacin, or doxycycline will inhibit the growth of the attenuated bacteria in the vaccine, preventing the development of an immune response. The vaccine should not be administered until at least 72 hours after the last dose of an antibiotic. Conversely, antibiotics should not be started for at least 3 days after the final dose of the oral vaccine series.

• Antimalarial Agents: Certain antimalarials, specifically Mefloquine and Proguanil, may interfere with the immune response to the oral Ty21a vaccine. It is generally recommended that the oral vaccine series be completed at least 3 days before starting these antimalarials. Chloroquine and Atovaquone/Proguanil (Malarone) appear to have less interaction, but timing should still be discussed with a travel medicine specialist.
• Other Live Vaccines: When taking the oral S. Typhi vaccine, other live oral vaccines (like the oral polio or rotavirus vaccine) should ideally be spaced apart by at least 4 weeks, or administered simultaneously if specifically studied, to avoid immune interference.

• Immunosuppressants: Drugs that suppress the immune system, such as azathioprine, cyclosporine, or TNF-inhibitors (e.g., adalimumab), can reduce the effectiveness of both the oral and injectable vaccines. While not strictly contraindicated for the injectable form, the patient may not be fully protected against typhoid after vaccination.
• High-Dose Corticosteroids: Patients on high doses of prednisone (e.g., >20 mg/day for more than 2 weeks) should delay vaccination until the steroid dose is reduced, as the immune response may be blunted.

Food is a major factor for the oral Ty21a vaccine. The vaccine must be taken on an empty stomach, at least one hour before a meal. Taking the vaccine with food can stimulate stomach acid production, which may neutralize the live attenuated bacteria before they reach the intestine. Additionally, the capsules should only be taken with cold or lukewarm water; hot beverages (coffee, tea) can kill the live organisms.

There are no well-documented interactions between S. Typhi vaccines and common herbal supplements like St. John's Wort or Ginkgo Biloba. However, any supplement that affects gut motility or immune function should be discussed with a provider. Probiotics should generally be avoided on the days the oral vaccine is taken to ensure there is no competition for colonization in the gut lymphoid tissue.

Salmonella Enterica Enterica Serovar Typhi vaccination can lead to a false-positive result on certain diagnostic tests for typhoid fever, such as the Widal test (an older serological test). If a patient requires testing for an active infection shortly after vaccination, healthcare providers should use culture-based methods (blood or stool culture) rather than serology to ensure accuracy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any recent antibiotics or antimalarials.

Salmonella Enterica Enterica Serovar Typhi vaccines must NEVER be used in the following circumstances:

• Severe Allergic Reaction: Any individual who has had a life-threatening allergic reaction (anaphylaxis) to a previous dose of the vaccine or any of its components (e.g., gelatin, lactose, or the Vi polysaccharide) must not receive further doses.
• Immunodeficiency (Oral Vaccine Only): The live attenuated Ty21a vaccine is absolutely contraindicated in patients with primary or acquired immunodeficiency. This includes patients with HIV/AIDS, those undergoing organ transplants, or those with congenital immune disorders. The risk is that the attenuated strain could revert or cause a disseminated infection in the absence of a functional immune system.
• Acute Febrile Illness: Vaccination should be delayed if the patient has a high fever or a severe acute illness, as this can complicate the assessment of side effects and potentially interfere with the immune response.

• Pregnancy: While not an absolute contraindication, the use of S. Typhi vaccines in pregnant women is generally avoided unless the risk of contracting typhoid fever is high. The injectable Vi polysaccharide is usually preferred over the live oral version in this scenario.
• Inflammatory Bowel Disease (IBD): Patients with active ulcerative colitis or Crohn's disease should use the oral vaccine with caution, as the underlying gut inflammation may affect the vaccine's efficacy or exacerbate GI symptoms.
• Persistent Diarrhea: Any condition causing rapid gastric emptying or malabsorption may reduce the time the oral vaccine stays in the gut, potentially lowering its effectiveness.

There is potential cross-sensitivity for patients who are allergic to other vaccines produced using similar methods or containing similar stabilizers. For instance, the oral capsule contains gelatin; patients with a known severe allergy to gelatin (found in some other vaccines like MMR or Varicella) should exercise extreme caution or opt for the injectable form if it is gelatin-free.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous vaccine reactions, before prescribing Salmonella Enterica Enterica Serovar Typhi.

Salmonella Enterica Enterica Serovar Typhi vaccines are classified as Pregnancy Category C by the FDA. This means that adequate and well-controlled studies in pregnant women have not been conducted. It is not known whether the vaccine can cause fetal harm or affect reproduction capacity. However, because typhoid fever itself is a severe risk to both the mother and the fetus (potentially causing miscarriage or preterm labor), vaccination may be considered if the risk of exposure is high. In such cases, the inactivated injectable Vi polysaccharide vaccine is typically preferred over the live attenuated oral vaccine to eliminate any theoretical risk of live bacterial transmission to the fetus.

It is not known whether S. Typhi antigens or the resulting antibodies are excreted in human milk. However, most vaccines are not considered a risk to breastfeeding infants. Because the oral vaccine is live attenuated but non-pathogenic in healthy individuals, and the injectable form is a purified polysaccharide, breastfeeding is generally not a contraindication. Mothers should discuss the risks and benefits with their healthcare provider, especially if the infant has any known immune system issues.

As previously noted, the age of the child determines which formulation is appropriate. The injectable Vi polysaccharide vaccine is approved for children 2 years of age and older. The oral Ty21a vaccine is approved for children 6 years of age and older, primarily because younger children may have difficulty swallowing the capsules whole and their immune systems may not respond as effectively to the oral live strain. Safety and effectiveness in infants under 2 years of age have not been established.

Clinical trials of S. Typhi vaccines did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, the elderly may have a less robust immune response (immunosenescence). However, the safety profile appears similar to that in younger adults. For elderly travelers, the choice between oral and injectable forms should be based on their ability to follow the oral dosing schedule and any underlying comorbidities.

There is no evidence that renal impairment affects the safety or efficacy of Salmonella Enterica Enterica Serovar Typhi vaccines. Since the vaccine components are not systemically absorbed and excreted by the kidneys in significant amounts, no dosage adjustment is necessary for patients with chronic kidney disease or those on dialysis.

Specific studies in patients with hepatic impairment have not been conducted. However, given the mechanism of action and the localized nature of the immune response (especially for the oral form), liver disease is not expected to significantly alter the vaccine's profile. Patients with severe liver disease should still be monitored for systemic reactions.

> Important: Special populations require individualized medical assessment to weigh the risks of the vaccine against the significant dangers of typhoid fever infection.

Salmonella Enterica Enterica Serovar Typhi vaccines function by inducing active immunity. The live attenuated Ty21a strain is a "rough" mutant of S. Typhi that lacks the Vi capsular polysaccharide and has a defect in the galE gene. This defect causes the bacteria to accumulate toxic metabolites when exposed to galactose, leading to bacterial lysis (cell death) after a few rounds of replication in the human gut. This limited replication is sufficient to stimulate the Gut-Associated Lymphoid Tissue (GALT), inducing secretory IgA and cell-mediated immune responses. The injectable Vi capsular polysaccharide vaccine consists of the purified Vi antigen. This antigen is a linear homopolymer of N-acetyl-galactosaminuronic acid. It triggers B-lymphocytes to produce specific IgG antibodies that circulate in the blood, providing systemic protection.

The pharmacodynamic effect is measured by seroconversion (the development of specific antibodies). For the injectable vaccine, protective levels of antibodies are usually reached within 14 days of administration. For the oral vaccine, the immune response develops more gradually over the course of the four-dose regimen and the following week. The duration of effect for the injectable form is approximately 2 years, while the oral form provides protection for up to 5 years in most individuals. Tolerance does not develop as it is not a chronic drug, but the immune response naturally wanes over time.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Immunological) |

| Protein Binding | N/A |

| Half-life (Antibodies) | 2 - 7 Years |

| Tmax (Antibody Peak) | 14 - 28 Days |

| Metabolism | Proteolysis/Saccharolysis |

| Excretion | Fecal (Live strain only) |

The oral vaccine contains the Ty21a strain of Salmonella Typhi, which is a live, attenuated bacterium. The injectable form contains the purified Vi capsular polysaccharide, which is a complex carbohydrate extracted from the Ty2 strain of S. Typhi. The molecular weight of the Vi polysaccharide is high, often exceeding 1,000 kDa. It is soluble in water and isotonic saline solutions.

Salmonella Enterica Enterica Serovar Typhi is classified as a Bacterial Vaccine (Active Immunizing Agent). It sits alongside other travel vaccines like the Yellow Fever vaccine and the Japanese Encephalitis vaccine. Within the EPC framework, it is uniquely categorized as a Non-Standardized Food Allergenic Extract when used in certain diagnostic contexts.